PMID- 11952003
OWN - NLM
STAT- MEDLINE
DCOM- 20021010
LR  - 20190822
IS  - 0803-5253 (Print)
IS  - 0803-5253 (Linking)
VI  - 91
IP  - 2
DP  - 2002
TI  - Alteration of biochemical profiles after high-dose intravenous immunoglobulin 
      administration in Kawasaki disease.
PG  - 164-7
AB  - Intravenous immunoglobulin (IVIG) has been used as an immunomodulatory treatment 
      for several immune-mediated diseases. Early effects of high-dose IVIG treatment 
      on biochemical profiles including lipids and proteins were evaluated in patients 
      with Kawasaki disease (KD). Twelve children with KD (9 boys) were treated with 
      IVIG at 2 g/kg over a period of 12 h. Serial sera samples were collected from the 
      patients four times: before IVIG treatment and 2 h, 24 h and 7 d after IVIG 
      treatment. The samples were frozen at -20 degrees C before biochemical analysis. 
      A significant decrease in albumin concentration was found 2 h and 24 h after IVIG 
      treatment, but this recovered to the pretreatment level after 7 d. Total 
      cholesterol and triglyceride increased slightly after 7 d. A significant decrease 
      in HDL-cholesterol and C-reactive protein was seen 2 h and 24 h after IVIG 
      treatment. CONCLUSION: High-dose IVIG affects immediate changes in protein 
      profiles and HDL-cholesterol in KD. Changes in HDL-cholesterol induced by IVIG 
      may be the result of changes in systemic protein metabolism.
FAU - Lee, K Y
AU  - Lee KY
AD  - Department of Pediatrics, College of Medicine, The Catholic University of Korea, 
      Seoul, Republic of Korea.
FAU - Han, J W
AU  - Han JW
FAU - Lee, J S
AU  - Lee JS
FAU - Whang, K T
AU  - Whang KT
LA  - eng
PT  - Journal Article
PL  - Norway
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - C-Reactive Protein/analysis
MH  - Child, Preschool
MH  - Cholesterol, HDL/blood
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Infant
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*blood/drug therapy
EDAT- 2002/04/16 10:00
MHDA- 2002/10/11 04:00
CRDT- 2002/04/16 10:00
PHST- 2002/04/16 10:00 [pubmed]
PHST- 2002/10/11 04:00 [medline]
PHST- 2002/04/16 10:00 [entrez]
AID - 10.1080/080352502317285153 [doi]
PST - ppublish
SO  - Acta Paediatr. 2002;91(2):164-7. doi: 10.1080/080352502317285153.